Background : Nerve growth factor (NGF) has been suggested to participate in tumor progression and it can interact with its receptor p75 NGFR . In the present study, we investigated the expressions of NGF and p75 NGFR in hepatocellular carcinoma (HCC NGFR expression was observed at the sinusoids or around the large vessels. The HCCs expressing NGF, either in the tumor cells or the endothelial cells, showed a larger size than those HCCs that didn't express NGF. The NGF positive tumors showed a tendency toward a higher PCNA-labeling index than did the negative tumors. Conclusions : The changed localization of the NGF expression and the decreased expression of p75 NGFR are associated with hepatic carcinogenesis. We suggest that a NGF expression may contribute to the progression of HCC.
The liver is innervated by both sympathetic and parasympathetic fibers, and most of these fibers enter the liver in close association with the hepatic artery, portal vein or bile duct.
1 Furthermore, several studies have demonstrated that the autonomic nervous system participates in the regulation of the hepatic blood circulation and metabolism. 2, 3 There are 2 known types of hepatic innervation: 1) the innervation of parenchymal cells related to hepatic metabolism and regeneration; and 2) catecholaminecontaining nerve fibers that are in close contact with hepatocytes and the vasculatures.
Nerve growth factor (NGF) is a prototypic member of the neurotrophin family, and NGF is essential for the survival, differentiation and maintenance of neuronal cells in both central and peripheral nervous systems. 4 NGF is composed of αand β subunits in most tissues. 4 Moreover, the biological activity of NGF is confined to its βsubunit, whereas both subunits are believed to be required for protection from proteolytic degradation. NGF can interact with two types of membrane binding sites: TrkA and p75
NGFR is a low affinity NGF receptor that structurally resembles members of the p55 tumor necrosis factor receptor family and it activates Jun N-terminal kinase and ceramide to promote apoptosis. [6] [7] [8] On the other hand, TrkA is a high affinity receptor with tyrosine kinase activity, and binding of TrkA with NGF results in intracellular signaling through the mitogen-activated protein kinase cascade and the phosphatidylinositol-3 kinase cascade, which both lead to the differentiation and survival of neuronal cells. [6] [7] [8] Several recent reports have indicated that NGF is involved in the repair of lung and skin tissue, in addition to its known involvements in allergic inflammation and fibrosis 9,10 and these reports have suggested that NGF is in-volved in tumor growth, invasion, and metastasis. 11-14 NGF and its two receptors are expressed in various cancers, including lung, breast and prostatic cancers, which suggests that NGF participates in tumorigenesis via the autocrine or paracrine pathways. 11, 13, 14 However, the role of NGF in cancer progression remains controversial.
Human hepatocellular carcinoma (HCC) is the fifth most common type of malignancy and it is the third leading cause of cancer death worldwide. 15 Despite the recent advances in diagnostic and therapeutic advances in the treatment of HCC, its prognosis is still poor. Without treatment, HCC that is diagnosed at an advanced stage usually leads to death within months, and any long-term survival is rare.
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The previous investigations that focused on the expressions of NGF and its receptors in HCC tissues have yielded contradictory results. Some researchers have found that hepatocytes expressed NGF and TrkA only in the walls of the arteries that are associated with tumors 17,18 whereas other researchers found that the hepatocytes in fibrotic rat livers expressed TrkA mRNA, but not NGF mRNA.
19 Thus, it is unclear which liver tissue cell types are involved in the cross-talk mediated by NGF during the progression of HCC.
In this study, we investigated the expressions and localizations of NGF and its receptor p75 NGFR in both HCC and the non-tumorous liver tissues. In addition, we examined the relationships between the clinicopathologic factors and the expressions of NGF and p75
NGFR in HCC and the relationships between the proliferating cell nuclear antigen-labeling index (PCNA-LI) and the expressions of NGF and p75 NGFR .
MATERIALS AND METHODS

Patients and specimens
This study was approved by the Human Ethics Committee of Chonbuk National University Hospital, Korea. We retrospectively studied the HCC specimens and the non-tumor specimens obtained from 45 patients who underwent surgical resection between 1991 and 2001 at the Chonbuk National University Hospital. None of the patients had received any therapy prior to surgery. Of the 45 patients with HCC, 37 were men and 8 were women. The mean patient age was 55.5 years (range: 12-79 years). The grading system developed by Edmondson and Steiner was used for histological grading the HCC. 20 The clinicopathologic findings of these specimens are summarized in Table 1 .
Immunohistochemistry
An immunoperoxidase method with employing streptavidinbiotinylated horseradish peroxidase complex (DAKO, Carpinteria, CA, USA) was used. Tissue blocks that contained non-tumor liver tissues and HCC tissues were selected and then 4 μ m thick sections were cut from the formalin-fixed, paraffin-embedded tissue blocks. After deparaffinization, the sections were subjected to a microwave antigen retrieval procedure in 0.01 M sodium citrate buffer for 10 min. The sections were then incubated in methanol that contained 0.3% hydrogen peroxide at room temperature for 20 min to block the endogenous peroxidase activity. After blocking the endogenous biotin, the sections were incubated with Protein Block Serum-Free (DAKO, Carpinteria) at room temperature for 10 min to block any nonspecific staining, and then the sections were incubated for 2 h at room temperature with anti-NGF (Santa Cruz Biotechnology, Santa Cruz, CA, USA), p75
NGFR (DAKO, Carpinteria) and PCNA (DAKO, Carpinteria) antibodies. After washing, the sections were incubated with a biotin-conjugated secondary antibody at room temperature for 30 min and they were finally incubated with peroxidase conjugated streptavidin at room temperature for 30 min. The peroxidase activity was detected with the enzyme substrate 3 amino-9-ethyl carbazole. For negative controls, sections were treated in the same manner except they were treated with Trisbuffered saline instead of the primary antibody.
Evaluation of the immunohistochemical results
To semi-quantitatively determine the expressions of NGF and p75 NGFR , a scoring system was developed by multiplying the degree of the staining intensities and the percentage of the positively stained areas. The intensities of cell staining were graded according to the following scale: 0, no staining; 1+, mild staining; 2+, moderate staining; 3+, marked staining, and the areas of staining were evaluated by using the following scale: 0, <10% of the cells stained positively; 1+, 10-30% of the cells stained positively; 2+, 30-70% of the cells stained positively; and 3+, >70% of the cells stained positively. Accordingly, the maximum possible score was 9 and the minimum possible score was zero. Specimens with scores >2 were considered positive for a NGF expression or a p75
NGFR expression. PCNA-LI was defined as the percentage of tumor cell nuclei that showed positive PCNA staining.
Statistical analysis
The expressions of NGF and p75 NGFR in the tumor and nontumor tissues were compared using Fisher's exact test. The possible relations between the clinicopathologic factors and the expressions of NGF or p75 NGFR in the tumor tissues were assessed by using Fisher's exact test. The relations between the NGF and p75
NGFR expressions in the tumor tissues and the PCNA-LI values were assessed by using Student's t-test. p-values <0.05 were considered statistically significant.
RESULTS
The expression of NGF and its relation with the clinicopathologic factors
In the non-tumor liver tissues, a NGF expression was observed in the sinusoidal endothelial cells (Fig. 1A) and the hepatocytes. In addition, a NGF expression was also observed in the epithelial cells of the bile ductules, in the nerve bundle cells and in the stromal cells. In the HCC tissues, NGF was found to be highly expressed in the tumor cells, which showed an intense cytoplasmic expression and in the sinusoidal endothelial cells (Fig. 1B, C) . Furthermore, NGF was detected in the tumor cells in 84.4% (38/45 cases) of the cases, and in the non-tumor hepatocytes in 64.4% (29/45 cases) of the cases (Table 2) , and the NGF expression had a tendency to exchange its localization between the tumor hepatocytes and the non-tumor hepatocytes (p=0.052). Moreover, while NGF was detected in the tumor endothelial cells in only 28.9% (13/45 cases) of the cases, it was detected in the nontumor endothelial cells in 80.0% (36/45 cases) of the cases, and the difference was significant (p<0.001). As shown in Table 3 , a NGF expression in the tumor cells was associated with a larger tumor size (p=0.034). In addition, a NGF expression in the Fig. 1 . In non-tumor liver tissues, NGF was present in sinusoidal endothelial cells (A). In HCC tissues, NGF was highly expressed in tumor cells (B) and in sinusoidal endothelial cells (C).
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tumor endothelial cells was associated an advanced age (p=0.047), the female gender (p=0.034) and a larger tumor size (p=0.042).
No other clinicopathologic factors were found to be correlated with the expression of NGF in HCC.
The expression of p75 NGFR and its relation with the clinicopathologic factors
In the non-tumor liver tissue, p75
NGFR was expressed in the nerve fibers in the portal areas ( Fig. 2A) , and especially around the blood vessels (Fig. 2B ) and the bile ducts in all cases (45/45 cases, Table 2 ). However, in the tumor tissues, p75
NGFR showed positivity in 42.2% (19/45 cases) of the cases in the nerve fibers, and especially in the nerve fibers around the large tumor vessels (Fig. 2C) . No tumor cells expressed p75 NGFR . The expression of p75 NGFR in the tumor tissues was significantly lower than that in the non-tumor liver tissues (p<0.001). As shown in Table 4 , none of the clinicopathologic factors were found to be correlated with a p75 NGFR expression.
Correlations between the expressions of NGF or p75
NGFR and the PCNA-LI values
The PCNA-LI values in the tumor tissues ranged from 12% to 79% (average: 40.6%). As shown in Table 5 , the tumors with cells expressing NGF tended to have higher PCNA-LI values than did those tumors that did not express NGF (p=0.054). There was no significant correlation between the NGF expression in the tumor endothelial cells and the PCNI-LI or between the p75 NGFR expression in tumor and the PCNI-LI was found.
DISCUSSION
This study demonstrates the following: 1) the expression of NGF was significantly lower in the tumor endothelial cells than that in the non-tumor endothelial cells, but there was a tendency for a higher NGF expression in the tumor cells than that in the non-tumor hepatocyes; 2) the expression of p75 NGFR was significantly lower in tumor tissues than that in the non-tumor tissues; NGFR was expressed in nerve fibers in portal areas (A), especially around blood vessels (B). In HCC tissues, p75
NGFR was not expressed in tumor cells but was expressed in the nerve fibers, especially around large tumor vessels (C). 3) the expression of NGF in either the tumor cells or the tumor endothelial cells was associated with a larger tumor size; 4) the HCCs with NGF-expressing tumor cells tended to have higher PCNA-LI values than did those HCCs with tumor cells that did not express NGF. These findings suggest that both the changed localization of the NGF expression and the decreased expression of p75 NGFR are associated with hepatic carcinogenesis. Furthermore, these results suggest that a NGF expression may contribute to the progression of HCC in association with the increased proliferation of tumor cells. The liver is innervated by two separate but intercommunicating plexuses that are around the hepatic artery and the portal vein. 21 Besides their presence around vascular structures in the portal tracts, nerve fibers, and mostly sympathetic nerve fibers, are present in the parenchyma along the sinusoids. Furthermore, the release of neurotransmitters from the intrasinusoidal fibers modulates the functions of the hepatocytes and perisinusoidal cells and this partly controls carbohydrate and lipid metabolism, and it induces the contractions of perisinusoidal cells, thereby regulating the intrasinusoidal blood flow.
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NGF can interact with two types of cell membrane receptors, i.e., TrkA and p75
NGFR
. 5 It has been demonstrated that NGF induces cell proliferation in breast cancer cell lines via TrkA and the activation of its downstream mitogen-activated protein kinase cascade.
14 In addition, NGF's effect on cell survival in breast cancer cell lines has been shown to be dependent on the activation of p75
NGFR and its downstream NFκ B signal cascade. 23 Both types of NGF receptor may participate in tumor progression by promoting cell proliferation and preventing apoptosis. Recent evi- NGFR homodimers mediate cell death.
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In recent years, many studies have concluded that NGF is involved in tumor biology, such as in growth, invasion and metastasis, and the expressions of NGF and/or of its receptors have been reported in many types of carcinomas.
14,25-27 In particular, Kishibe et al. 17 showed that NGF is expressed in mouse HCC tissues and mouse HCC cell lines at much higher levels than that in a normal liver, and immunostaining showed that NGF is expressed not only in HCCs, but also in early preneoplastic lesions, which indicates that its expression represents an early change during murine hepatic carcinogenesis. In addition, Rasi et al. 28 reported that NGF is expressed in human tissues with cirrhosis and HCC, but not in normal liver tissues or in the liver tissues with cirrhosis and without HCC. Further, these researchers showed that NGF was mainly localized on tumor hepatocytes, and to a lesser extent on the endothelial cells and Kupffer cells in HCC tissues. However, NGF was localized on the biliary epithelial cells and hepatic stellate cells in the cirrhotic tissues. The location that expressed NGF was similar to our results except that NGF was not expressed on the non-tumor hepatocytes. This difference of results might be partly due to the different sources of antibody. In the present study, NGF was found to be expressed at higher levels in the tumor cells than that in the non-tumor hepatocytes, which suggests that NGF participates in the tumorigenesis of HCC. Additionally, the HCCs with NGF expressing tumor cells tended to have higher proliferating activities. Even though p75
NGFR was remarkably expressed in the walls of the large vessels in HCC, its expression was not observed in tumor cells or in the non-tumor hepatocytes, which suggests that HCC tumor cells and normal hepatocytes are not the major targets of NGF. These results concur with those of a previous murine study, in which a NGF expression was observed in the neoplastic hepatocytes, but the expressions of TrkA and p75
NGFR were not observed in the tumor cells. 17 Furthermore, TrkA was observed in the walls of the hepatic arteries, and this might have contributed to the development of tumor-associated arteries. 17 The TrkA expression in the arterial walls suggests that NGF may enhance hepatic innervation and further promote blood vessel development, and that the NGF produced by HCC cells has a paracrine action toward the non-tumor cell components in the HCC tissues.
In agreement with our results, Yuanlong et al. 29 reported that the expression of p75NTR was significantly decreased in HCC tissues as compared with their adjacent noncancerous counterparts, and the up-regulation of p75
NGFR inhibited the growth of HCC cell lines by inducing cell cycle arrest. These results suggested that p75
NGFR might be a potential tumor suppressor. To sum it up, our findings suggest that the location showing a NGF expression is changed in HCC, and the NGF produced by the HCC tumor cells is a paracrine factor that participates in the progression of HCC. A deeper understanding of the role of neurotrophins in hepatic carcinogenesis might provide valuable clues for creating novel strategies to treat HCC.
